Overview

Marengo Therapeutics, an ATP company, is
developing the First-in-Class immune activators that stimulate and expand anti-tumor
T cells for long-term protection against cancer. Marengo’s antibodies induce
potent and durable anti-tumor responses in refractory solid tumor models and
promote protective tumor immunity (“immune memory”). Marengo’s lead project, a
first- and -best-in-class therapy with single agent potential, is progressing
to IND for several solid tumors with high-unmet medical needs. The company’s
advanced antibody discovery platform has also generated a pipeline of
multi-specific antibody therapies with potential in multiple tumor types.

See all Members